Teva Announces Prescription Copay Savings Program for Generic Gleevec® Tablets in the United States

People who meet certain requirements are eligible to participate and
may pay as little as $0 out-of-pocket

NORTH WALES, Pa.–(BUSINESS WIRE)–Teva Pharmaceuticals USA, a subsidiary of Teva Pharmaceutical Industries
Ltd., (NYSE and TASE: TEVA) today announced the launch of a prescription
copay assistance program in the U.S. for the Company’s generic
equivalent to Gleevec®1 (imatinib mesylate) tablets. Teva
launched imatinib mesylate tablets in the U.S. earlier this year.

People who meet certain requirements are eligible to participate in the
program and may pay as little as $0 out-of-pocket with a maximum benefit
of up to $700 per fill. The program applies to eligible patients who are
commercially insured. Savings are limited to copay amount and
eligibility restrictions, terms and conditions apply.

In compliance with applicable laws and regulations, the program is not
available to patients who are covered under Medicaid, Medicare, a
Medicare Part D or Medicare Advantage plan (regardless of whether a
specific prescription is covered), TRICARE, CHAMPUS, Government Health
Insurance Plan (“Healthcare Reform”), or any other state or federal
medical or pharmaceutical benefit program or pharmaceutical assistance

“This effort further reinforces Teva’s long-standing commitment to
providing access to our medicines,” said Andy Boyer, President & CEO,
Global Generic Medicines, North America at Teva. “Given today’s economic
climate, programs that help alleviate the high copay costs that many
patients face are increasingly important.”

Eligible patients can enroll in the program and receive additional
information about copay assistance by visiting
or calling 1-844-546-8639.

Teva remains committed to strengthening its generics business with
continued investment in new and diverse, high quality products. With
nearly 600 generic medicines available, Teva has the largest portfolio
of FDA-approved generic products on the market and holds the
leading position in first-to-file opportunities, with over 100 pending
first-to-files in the U.S. Currently, one in seven generic prescriptions
dispensed in the U.S. is filled with a Teva generic product.

About Teva

Teva Pharmaceuticals USA, Inc., a wholly-owned subsidiary of
Israeli-based Teva Pharmaceutical Industries Ltd., the global leader in
generics and one of the leading pharmaceutical companies in the world.
Teva’s extensive U.S. operations are headquartered near Philadelphia,
PA. Teva Generics leverages its portfolio of more than 1,800 molecules
to produce a wide range of generic products in nearly every therapeutic
area. For more information, visit

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995 , which
are based on management’s current beliefs and expectations and are
subject to substantial risks and uncertainties, both known and unknown,
that could cause our future results, performance or achievements to
differ significantly from that expressed or implied by such
forward-looking statements. Important factors that could cause or
contribute to such differences include risks relating to:

  • commercial success of Teva’s generic version of imatinib
  • our generics medicines business, including: that we are
    substantially more dependent on this business, with its significant
    attendant risks, following our acquisition of Allergan plc’s worldwide
    generic pharmaceuticals business (“Actavis Generics”); our ability to
    realize the anticipated benefits of the acquisition (and any delay in
    realizing those benefits) or difficulties in integrating Actavis
    Generics; the increase in the number of competitors targeting generic
    opportunities and seeking U.S. market exclusivity for generic versions
    of significant products; price erosion relating to our generic
    products, both from competing products and as a result of increased
    governmental pricing pressures; and our ability to take advantage of
    high-value biosimilar opportunities;
  • our business and operations in general, including: uncertainties
    relating to our recent senior management changes; our ability to
    develop and commercialize additional pharmaceutical products;
    manufacturing or quality control problems, which may damage our
    reputation for quality production and require costly remediation;
    interruptions in our supply chain; disruptions of our or third party
    information technology systems or breaches of our data security; the
    failure to recruit or retain key personnel, including those who joined
    us as part of the Actavis Generics acquisition; the restructuring of
    our manufacturing network, including potential related labor unrest;
    the impact of continuing consolidation of our distributors and
    customers; variations in patent laws that may adversely affect our
    ability to manufacture our products; adverse effects of political or
    economic instability, major hostilities or terrorism on our
    significant worldwide operations; and our ability to successfully bid
    for suitable acquisition targets or licensing opportunities, or to
    consummate and integrate acquisitions; and
  • compliance, regulatory and litigation matters, including: costs and
    delays resulting from the extensive governmental regulation to which
    we are subject; the effects of reforms in healthcare regulation and
    reductions in pharmaceutical pricing, reimbursement and coverage;
    potential additional adverse consequences following our resolution
    with the U.S. government of our FCPA investigation; governmental
    investigations into sales and marketing practices; potential liability
    for sales of generic products prior to a final resolution of
    outstanding patent litigation; product liability claims; increased
    government scrutiny of our patent settlement agreements; failure to
    comply with complex Medicare and Medicaid reporting and payment
    obligations; and environmental risks.

and other factors discussed in our Annual Report on Form 20-F for the
year ended December 31, 2016 (“Annual Report”) and in our other filings
with the U.S. Securities and Exchange Commission (the “SEC”).
Forward-looking statements speak only as of the date on which they are
made, and we assume no obligation to update or revise any
forward-looking statements or other information contained herein,
whether as a result of new information, future events or otherwise.
are cautioned not to rely on these forward-looking statements. You are
advised to consult any additional disclosures we make in our reports to
the SEC on Form 6-K, as well as the cautionary discussion of risks and
uncertainties under “Risk Factors” in our Annual Report. These are
factors that we believe could cause our actual results to differ
materially from expected results. Other factors besides those listed
could also materially and adversely affect us. This discussion is
provided as permitted by the Private Securities Litigation Reform Act of

1 GLEEVEC® is a registered trademark of Novartis


Teva Pharmaceuticals USA, Inc.
PR Contacts:
United States
, 215-591-8974
Elizabeth DeLuca,